Ginkgo Bioworks Holdings: Hold Rating Amidst Revenue Growth and Restructuring Efforts
In a report released yesterday, Tejas Savant from Morgan Stanley maintained a Hold rating on Ginkgo Bioworks Holdings (DNA – Research Report), ...
Business Insider12h
Balanced Hold Recommendation for Adaptive Biotechnologies Amid Positive Performance and External Challenges
Savant covers the Healthcare sector, focusing on stocks such as Myriad Genetics, Guardant Health, and Ginkgo Bioworks Holdings. According to TipRanks, Savant has an average return of -4.5% and a 40.00 ...
NVIDIA Opens BioNeMo to Scale Digital Biology for Global Biopharma and Scientific Industry
Argonne National Laboratory, Flagship Pioneering, Terray, Weights & Biases and Dozens More Organizations Among Contributors ...
Ginkgo Bioworks: Unproven Transition But 2025 Is Looking Better
Analysis of Ginkgo Bioworks' Q3 results and business model, with a focus on growth, customer acquisition and cash flow ...